Chardan Capital Reiterates Buy on Iovance Biotherapeutics, Maintains $29 Price Target
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Geulah Livshits has reiterated a 'Buy' rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintained a price target of $29.
July 11, 2023 | 8:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital has reiterated a 'Buy' rating on Iovance Biotherapeutics and maintained a price target of $29.
The reiteration of a 'Buy' rating by Chardan Capital indicates a positive outlook for Iovance Biotherapeutics. The maintained price target of $29 suggests that the analyst believes the stock has potential for growth. This could positively impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100